目的探討誘導型一氧化氮合酶(iNOS)抑制劑氨基胍對內(nèi)毒素休克大鼠肝臟的組織學和超微結(jié)構(gòu)的影響。方法取雄性Wistar大鼠24只,隨機分為正常對照組、內(nèi)毒素對照組和氨基胍治療組,每組各8只。用大腸桿菌內(nèi)毒素(LPS)復制大鼠內(nèi)毒素性休克模型,氨基胍治療組采用氨基胍治療。觀察并比較三組大鼠肝臟的組織學、超微結(jié)構(gòu)及其血漿一氧化氮(NO)含量的變化。結(jié)果光鏡下可見,內(nèi)毒素組肝組織有散在小膿腫灶形成,肝細胞壞死,中性白細胞浸潤,而氨基胍治療組的肝組織受損程度較輕。電鏡下可見,內(nèi)毒素組的肝細胞核出現(xiàn)融解性空斑,線粒體腫脹和線粒體嵴數(shù)量減少,而氨基胍則對肝臟的結(jié)構(gòu)起到一定的保護作用。內(nèi)毒素對照組血漿NO水平明顯高于正常對照組,給予氨基胍治療后血漿NO水平明顯下降,但仍高于正常對照組。結(jié)論氨基胍通過選擇性抑制iNOS活性,抑制了大鼠內(nèi)毒素休克時過量的NO的產(chǎn)生,保護了肝臟的功能,具有潛在的臨床應(yīng)用價值,值得更深入地研究。
引用本文: 宋文哲,宋燕,譚巖,尹家俊. 氨基胍對內(nèi)毒素休克大鼠肝損傷的保護作用研究. 中國普外基礎(chǔ)與臨床雜志, 2003, 10(4): 347-350. doi: 復制
版權(quán)信息: ?四川大學華西醫(yī)院華西期刊社《中國普外基礎(chǔ)與臨床雜志》版權(quán)所有,未經(jīng)授權(quán)不得轉(zhuǎn)載、改編
1. | Ruetten H, Southan GJ, Abate A, et al. Attenuation of endotoxininduced multiple organ dysfunction by 1amino2hydroxyguanidine, a potent inhibitor of inducible nitric oxide synthase [J]. Br J Pharmacol, 1996; 118(2)∶261. |
2. | Witte K, Schnecko A, Zuther P, et al. Contribution of the nitric oxideguanylyl cyclase system to circadian regulation of blood pressure in normotensive WistarKyoto rats [J]. Cardiovasc Res, 1995; 30(5)∶682. |
3. | Yang F, Comtois AS, Fang L, et al. Nitric oxidederived nitrate anion contributes to endotoxic shock and multiple organ injury/dysfunction [J]. Crit Care Med, 2002; 30(3)∶650. |
4. | Moncada S, Higgs A. The Largininenitric oxide pathway [J]. N Eng J Med, 1993; 329(27)∶2002. |
5. | Thiemermann C .The role of the Larginine: nitric oxide pathway in circulatory shock [J]. Adv Pharmacol, 1994; 28(1)∶45. |
6. | Brealey D, Brand M, Hargreaves I, et al. Association between mitochondrial dysfunction and severity and outcome of septic shock [J]. Lancet, 2002; 360(9328)∶219. |
7. | Morris SM Jr, Billiar TR. New insights into the regulation of inducible nitric oxide synthesis [J]. Am J Physiol, 1994; 266(6 Pt 1)∶E829. |
8. | Billiar TR, Curran RD, Stuehr DJ, et al. An Largininedependent mechanism mediates Kupffer cell inhibition of hepatocyte protein synthesis in vitro [J]. J Exp Med, 1989; 169(4)∶1467. |
9. | Nathan C. Nitric oxide as a secretory product of mammalian cells [J]. FASEB J, 1992; 6(12)∶3051. |
- 1. Ruetten H, Southan GJ, Abate A, et al. Attenuation of endotoxininduced multiple organ dysfunction by 1amino2hydroxyguanidine, a potent inhibitor of inducible nitric oxide synthase [J]. Br J Pharmacol, 1996; 118(2)∶261.
- 2. Witte K, Schnecko A, Zuther P, et al. Contribution of the nitric oxideguanylyl cyclase system to circadian regulation of blood pressure in normotensive WistarKyoto rats [J]. Cardiovasc Res, 1995; 30(5)∶682.
- 3. Yang F, Comtois AS, Fang L, et al. Nitric oxidederived nitrate anion contributes to endotoxic shock and multiple organ injury/dysfunction [J]. Crit Care Med, 2002; 30(3)∶650.
- 4. Moncada S, Higgs A. The Largininenitric oxide pathway [J]. N Eng J Med, 1993; 329(27)∶2002.
- 5. Thiemermann C .The role of the Larginine: nitric oxide pathway in circulatory shock [J]. Adv Pharmacol, 1994; 28(1)∶45.
- 6. Brealey D, Brand M, Hargreaves I, et al. Association between mitochondrial dysfunction and severity and outcome of septic shock [J]. Lancet, 2002; 360(9328)∶219.
- 7. Morris SM Jr, Billiar TR. New insights into the regulation of inducible nitric oxide synthesis [J]. Am J Physiol, 1994; 266(6 Pt 1)∶E829.
- 8. Billiar TR, Curran RD, Stuehr DJ, et al. An Largininedependent mechanism mediates Kupffer cell inhibition of hepatocyte protein synthesis in vitro [J]. J Exp Med, 1989; 169(4)∶1467.
- 9. Nathan C. Nitric oxide as a secretory product of mammalian cells [J]. FASEB J, 1992; 6(12)∶3051.